ClinicalTrials.gg
Not yet recruitingNCT07609875Updated May 27, 2026

A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension

A Phase 1 interventional study of HS-10522 and HS-10522 Placebo in Healthy Adult and Hypertension, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with mild hypertension.

02

Conditions studied

  • Healthy Adult
  • Hypertension

Browse trials for

Keywords

  • hypertension
03

In context

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

This study's planned enrollment of 88 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

For all participants:

  1. Able to understand the procedures and methods of the study, willing to strictly adhere to the clinical trial protocol to complete the study, and voluntarily sign the Form (ICF).
  2. Male or female participants aged 18 to 55 years (inclusive) at the time of signing ICF.
  3. At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females, with a (BMI) between 19.0 and 28.0 kg/m² (inclusive).

Exclusion criteria

Exclusion Criteria:

  1. Abnormal vital signs, physical examination findings, or laboratory test results at screening that are deemed by the investigator.
  2. Presence of orthostatic hypotension or orthostatic tachycardia at screening.
  3. Clinically significant abnormal findings on the 12-lead at screening, as judged by the investigator.
  4. Use of any medication within 2 weeks or 5 half-lives (whichever is longer) prior to screening, or anticipation of needing such medication during the trial.
  5. Known secondary causes of hypertension, or diseases that may affect adrenal function (e.g., renal artery stenosis, poorly controlled or untreated hyperthyroidism, poorly controlled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome).
  6. Participation in any other clinical trial of a drug or medical device within 12 weeks prior to screening, with receipt of at least one dose (including placebo), or currently within 5 half-lives of the last dose of the product (whichever is longer).
  7. Participants who, in the opinion of the investigator, are likely to be non-compliant or are unsuitable for participation in this trial for any other reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    HS-10522

    Drug: HS-10522

  • Placebo comparator
    HS-10522 Placebo

    Drug: HS-10522 Placebo

Interventions

  • DrugHS-10522

    HS-10522 tablet, oral, single ascending dose and multiple ascending dose, once daily

  • DrugHS-10522 Placebo

    HS-10522 placebo , oral, single ascending dose and multiple ascending dose, once daily

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events following single and multiple doses of HS-10522 in healthy participants and participants with mild hypertension

    Safety and tolerability will be assessed by comparison of number of adverse events between groups

    Time frame: SAD: 0 to 7 days after dosing; MAD: 0 to 14 days after dosing

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: -0.5 to 120 hour after dosing

  2. time to maximum plasma concentration (Tmax)

    Time frame: -0.5 to 120 hour after dosing

  3. area under the curve (AUC)

    Time frame: -0.5 to 120 hour after dosing

  4. half-life

    Time frame: -0.5 to 120 hour after dosing

  5. apparent volume of distribution (Vz/F)

    Time frame: -0.5 to 120 hour after dosing

  6. apparent oral clearance (CL/F) of HS-10522

    Time frame: -0.5 to 120 hour after dosing

  7. Plasma aldosterone following single and multiple oral doses of HS-10522

    Time frame: 0 to 96 hour after dosing

  8. Cortisol following single and multiple oral doses of HS-10522

    Time frame: 0 to 96 hour after dosing

  9. Metabolites levels following single and multiple oral doses of HS-10522

    Time frame: 0 to 96 hour after dosing

  10. (Exploratory) Mean seated systolic and diastolic blood pressure change compared with baseline

    Blood pressure measurement will be performed only in MAD part

    Time frame: 14 days after dosing

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 7 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 27, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 20, 2027
CompletionEst.
Feb 3, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07609875
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 20, 2027 (estimated)
Completion
Feb 3, 2027 (estimated)
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion